EMPEROR Preserved | EMPEROR Pooled Trial Results

Investigators Stefan Anker and Milton Packer summarize the results of EMPEROR-Preserved and EMPEROR -Pooled trials, the first to show a positive result for a possible treatment for patients with heart failure with preserved ejection fraction with or without diabetes--the SGLT2 inhibitor empagliflozin.

[mahekshah]

And there is no impact on anything beyond HF hospitalization.